324784-91-0Relevant academic research and scientific papers
COMPOUNDS AND USES THEREOF
-
Page/Page column 168, (2020/08/13)
The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
-
Paragraph 0692, (2016/02/21)
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
Chemokine receptor antagonists and methods of use thereof
-
, (2008/06/13)
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.
Chemokine receptor antagonists and methods of use therefor
-
, (2008/06/13)
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: and physiologically acceptable salts thereof.
Chemokine receptor anagonists and methods of use therefor
-
, (2008/06/13)
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR
-
, (2008/06/13)
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: and physiologically acceptable salts thereof.
